Amanote Research
Register
Sign In
BCL2/MDM2 Inhibitor Combo Effective in AML
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2019-003
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
January 15, 2019
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Drug Combo May Be Effective in Ovarian Cancer
Cancer Discovery
Oncology
Targeted Combo Effective for Refractory Ewing Sarcoma
Cancer Discovery
Oncology
A New B-Raf Inhibitor Combo for Advanced Melanoma
Oncotarget
Oncology
Mutant IDH2 Inhibitor Looks Promising in AML
Cancer Discovery
Oncology
The BCL2 Inhibitor Venetoclax Is Active in Non-Hodgkin Lymphoma
Cancer Discovery
Oncology
Highly Effective Combination of LSD1 (KDM1A) Antagonist and Pan-Histone Deacetylase Inhibitor Against Human AML Cells
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML
Cancer Discovery
Oncology
Targeting Resistance Against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
Clinical Cancer Research
Cancer Research
Oncology
P53 Mediated Death of Cells Overexpressing MDM2 by an Inhibitor of MDM2 Interaction With P53
Oncogene
Cancer Research
Genetics
Molecular Biology